Earlier initiation of biologics in severe asthma (SA) is associated with higher rates of clinical remission and improved asthma control.
Delays in biologic treatment correlate with increased exacerbations, worsened lung function, and higher oral corticosteroid (OCS) burden.
Real-world global data from CHRONICLE, ISAR, and OPCRD cohorts reinforce the importance of timely biologic accessibility and prescription policy reforms.
Shifting asthma management from a ‘reserve’ to a ‘preserve’ approach could better maintain lung function and quality of life in patients with SA.
